Partner Profile

GlaxoSmithKline plc (GSK) is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. GSK has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes, and digestive conditions. GSK Biologicals develops and produces more than 30 prescribed vaccines worldwide to prevent potentially life-threatening or crippling illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis, among others.

Website: www.gsk.com

Role in the ADVANCE Project

GSK has extensive expertise in the development, marketing, surveillance and benefit - risk assessment of vaccines. GSK acts as EFPIA partners coordinator in ADVANCE, as well as co-leading WPs 4 and 5 and contributing to the design, analysis, outcomes of studies and blueprint within all other workpackages, as well as to project management.

Key People

**Vincent Bauchau (PHD)**, Head of Vaccine Safety Research Group, Global Safety, GSK Vaccines. Vincent has 15 years experience as pharmacoepidemiologist in the Pharmaceutical Industry, spanning from disease epidemiology, outcomes research, pharmacovigilance to data mining. He is currently head of the Vaccine Safety Research group within the global vaccine safety department at GlaxoSmithKline Vaccines (Wavre, Belgium). His current interests focus on studies and methods for monitoring and evaluating the post-licensure safety profile of vaccines, from signal detection to quantitative benefit-risk monitoring. Before joining the Pharmaceutical Industry he had spent still a longer time in academic research.

**Germano Ferreira (PharmD, MPH, PHD)**, Lead, Observational Data Analytics, Global Epidemiology-Biostatistics, GSK Vaccines. Germano is a registered pharmacist, trained in epidemiology and pharmacoepidemiology, with 12 years of experience in the field of pharmacoepidemiology; ranging from regulatory, academic, and pharmaceutical industry settings. His research interest are the design and methodologies for
implementing observational studies (burden of disease and of health outcomes of interest, vaccine effectiveness and vaccine safety) to support development of new vaccines and vaccination strategies, using electronic health records and large databases.

**Graham Somers (PHD)**

Graham has 28 years of experience in Drug metabolism and pharmacokinetics in the pharmaceutical industry in a number of roles across the business. These include extensive input into early research of new targets to full development of number of small molecules that are now successfully marketed products in a number of disease areas. More recent experience has included matrix management of science innovation teams with external alliance partners and as alliance manager in the IMI group at GSK.